CHMP fandt det ikke berettiget at eksponere hele den tilsigtede målgruppe for beta - agonistrelaterede bivirkninger,
and adolescents with moderate persistent asthma for whom rapid control of asthma is essential, in section 4.2 of the SPC is acceptable.